Newbury Pharmaceuticals AB (publ) (NEWBRY.ST) Research

Newbury Pharmaceuticals AB (publ), a hybrid pharmaceutical enterprise, serves both the Swedish and wider Scandinavian markets. Formed in 2020 and headquartered in Lund, Sweden, the company provides a variety of therapeutic solutions, with a strong emphasis on oncology, rare diseases, and neurology, in addition to other treatment categories.

Market snapshot

Symbol
NEWBRY.ST
Price
$1.92
Day change
+1.59%
Market cap
$49.8M
P/E ratio
-2.08x
52-week range
0.76-7.88
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • AcouSort AB (publ) (ACOU.ST)
  • ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
  • Scandinavian Real Heart AB (Publ) (HEART.ST)
  • Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
  • ODI Pharma AB (ODI.ST)
  • OncoZenge AB (publ) (ONCOZ.ST)
  • Ortivus AB (publ) (ORTI-B.ST)
  • ScandiDos AB (publ) (SDOS.ST)

Open Newbury Pharmaceuticals AB (publ) (NEWBRY.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.